The 2012 southern African ARV drug resistance testing guidelines

Southern African Journal of HIV Medicine

Volumn 13, Issue 4, 2012, Pages 162-167

  Conradie, F ^a   Wilson, D ^a   Basson, A ^b   De Oliveira, T ^b   Hunt, G ^b   Joel, D ^b   Papathanasopoulos, M ^b   Preiser, W ^b   Klausner, J ^b   Spencer, D ^b   Stevens, W ^b   Venter, F ^b   Van Vuuren, C ^b   Levin, L ^b   Meintjes, G ^b   Orrell, C ^b   Sunpath, H ^b   Rossouw, T ^b   Van Zyl, G ^b  

^a Resistance Testing Guidelines Committee   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ALCOHOL CONSUMPTION; ANOREXIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFLICT OF INTEREST; COST EFFECTIVENESS ANALYSIS; DENIAL; DEPRESSION; DRUG MONITORING; DRUG TREATMENT FAILURE; FERTILITY; FOOD INSECURITY; GENOTYPE; GROUPS BY AGE; HEALTH CARE COST; HEALTH LITERACY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIPOATROPHY; MEDICATION THERAPY MANAGEMENT; MENTAL CONCENTRATION; MENTAL DISEASE; MIXED INFECTION; NAUSEA; NIGHTMARE; PATIENT ADVOCACY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; POLYMERASE CHAIN REACTION; POVERTY; PRACTICE GUIDELINE; SCALE UP; SEROCONVERSION; SHIFT WORKER; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL PROBLEM; SOCIAL STIGMA; SOMNOLENCE; SOUTH AFRICA; STANDARDIZATION; VERTICAL TRANSMISSION; VIRAL TROPISM; VIRUS LOAD; VIRUS MUTATION;

EID: 84873845926     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.4102/sajhivmed.v13i4.109     Document Type: Article

References (28)

1. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004;18(11):1503-1511.
2. World Health Organization (WHO). HIV Resistance Report, 2012. Geneva: WHO, 2012. http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html (accessed 9 October 2012).
3. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47(2):266-285. [http://dx.doi.org/ 10.1086/589297]
4. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13:1-85. [http://dx.doi.org/10.1111/j.1468-1293.2012. 01029.x]
5. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society - USA Panel. JAMA 2012;308(4):387-402. [http://dx.doi.org/ 10.1001/jama.2012.7961]
6. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A metaanalysis. Int J Epidemiol 2007;36;1009-1021. [http://dx.doi.org/ 10.1093/ije/dym104]
7. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
8. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: A systematic review. Lancet Infect Dis 2011;11(10):769-779. [http://dx.doi.org/10.1016/S1473-3099(11)70141- 4]
9. Sigaloff KC, Ramatsebe T, Vlana R, et al. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses 2012;28(2):171-175. [http://dx.doi.org/ 10.1089/aid.2011.0136]
10. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: Implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009;200(5):687-697. [http://dx.doi.org/10.1086/604731]
11. Cozzi-Lepri A, Paredes, Phillips AN, et al. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Med 2012;13(1):62-72. [http://dx.doi.org/10.1111/j.1468-1293.2011.00943.x]
12. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for ART naïve patients with subtype C HIV infection failing a TDF-containing first-line regimen in South Africa. AIDS 2012 (in press). [http://dx.doi.org/10.1097/QAD. 0b013e328356886d]
13. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/ r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011;769627.
14. Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, et al. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2011;58(3):304-308. [http://dx.doi.org/10.1097/QAI.0b013e3182278c29]
15. El-Khatib Z, Delong AK, Katzenstein D, et al. Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving nonnucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res 2011;2(117):1000117. [http://dx.doi.org/10.4172/2155-6113.1000117]
16. de Oliveira T, Shafer RW, Seebregts C. Public database for HIV drug resistance in southern Africa. Nature 2010;464(7289):673.
17. Lima V, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008;22:2371-2380. [http://dx.doi.org/10.1097/QAD.0b013e328315cdd3]
18. Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: longterm outcomes in South Africa. J Acquir Immune Defic Syndr 2012 (in press). [http://dx.doi.org/10.1097/QAI.0b013e3182615ad1]
19. Rueda S, Park-Wyllie LY, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database of Systematic Reviews 2006;3:CD001442. [http://dx.doi.org/10. 1002/14651858.CD001442.pub2]
20. Rosen S, Long L, Sanne I, Stevens WS, Fox MP. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Intl AIDS Soc 2011;14:24.
21. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after virologic failure of first-line antiretroviral therapy (ART) in a resource-limited setting: Initial results of the South Africa Resistance Cohort Study (SARCS). CID 2008;46:1589-1597.
22. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir ther 2007;12(1):83-88.
23. Nakasujja N, Skolasky RL, Musisi S, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry 2010;10:10-44. [http://dx.doi.org/10.1186/1471- 244X-10-44]
24. Sunpath H, Lu Z, Chelin N, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010;24(7):1007-1012.
25. Prosperi MC, Mackie N, Di Giambenedetto S, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 2011;66(8):1886-1896. [http://dx.doi.org/ 10.1093/jac/dkr171]
26. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004;39(7):1030-1037.
27. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359(4):339-354. [http://dx.doi.org/10.1056/NEJMoa0708975]
28. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806. [http://dx.doi.org/10.1016/S0140-6736(09) 60918-1]